Contineum Therapeutics, Inc. (CTNM)
NASDAQ: CTNM · Real-Time Price · USD
8.68
-0.36 (-3.98%)
At close: Nov 20, 2026, 4:00 PM EST
8.80
+0.12 (1.38%)
After-hours: Nov 20, 2026, 7:30 PM EST
Contineum Therapeutics Stock Forecast
Stock Price Forecast
According to 8 analysts polled by S&P Global, Contineum Therapeutics stock has a consensus rating of "Buy" and an average price target of $21.43. The average 1-year stock price forecast is 146.89% higher than the current stock price, while the lowest is $14 (+61.29%) and the highest is $30 (+245.62%).
Price Target: $21.43 (+146.89%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Contineum Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 | Nov '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 6 | 6 | 6 | 5 | 5 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 8 | 8 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | Morgan Stanley | Hold Reiterates $17 | Hold | Reiterates | $17 | +95.85% | Nov 18, 2026 |
| RBC Capital | RBC Capital | Buy Maintains $21 | Buy | Maintains | $21 | +141.94% | Nov 4, 2026 |
| JonesTrading | JonesTrading | Buy Reiterates $30 | Buy | Reiterates | $30 | +245.62% | Nov 4, 2026 |
| Robert W. Baird | Robert W. Baird | Hold Downgrades $19 → $14 | Hold | Downgrades | $19 → $14 | +61.29% | Oct 14, 2026 |
| Stifel Nicolaus | Stifel Nicolaus | Buy Reiterates $29 → $28 | Buy | Reiterates | $29 → $28 | +222.58% | Oct 12, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.79
from -2.17
EPS Next Year
-2.10
from -1.79
EPS and Forward PE are based on non-GAAP adjusted numbers.